These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3290717)

  • 21. Experience with cyclophosphamide in multiple sclerosis: the cons.
    Likosky WH
    Neurology; 1988 Jul; 38(7 Suppl 2):14-8. PubMed ID: 3290708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of digital technology to asses the severity of the Experimental Allergic Encephalomyelitis (EAE) spinal cord lesion.
    Mohamed A; Tarhuni H; Dufan T; Benghuzzi H; Tucci M
    Biomed Sci Instrum; 2004; 40():419-23. PubMed ID: 15133994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
    Madsen LS; Andersson EC; Jansson L; krogsgaard M; Andersen CB; Engberg J; Strominger JL; Svejgaard A; Hjorth JP; Holmdahl R; Wucherpfennig KW; Fugger L
    Nat Genet; 1999 Nov; 23(3):343-7. PubMed ID: 10610182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The T-cell response to myelin basic protein in familial multiple sclerosis: diversity of fine specificity, restricting elements, and T-cell receptor usage.
    Joshi N; Usuku K; Hauser SL
    Ann Neurol; 1993 Sep; 34(3):385-93. PubMed ID: 7689820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experience with use of plasmapheresis in chronic progressive multiple sclerosis: the pros.
    Khatri BO
    Neurology; 1988 Jul; 38(7 Suppl 2):50-2. PubMed ID: 3290715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cop 1 therapy for multiple sclerosis.
    Weiner HL
    N Engl J Med; 1987 Aug; 317(7):442-4. PubMed ID: 3302706
    [No Abstract]   [Full Text] [Related]  

  • 27. Myelin basic protein administration in multiple sclerosis.
    Campbell B; Vogel PJ; Fisher E; Lorenz R
    Arch Neurol; 1973 Jul; 29(1):10-5. PubMed ID: 4123119
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report.
    Abramsky O; Teitelbaum D; Arnon R
    J Neurol Sci; 1977 Apr; 31(3):433-8. PubMed ID: 845620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune modulating peptides for the treatment and suppression of multiple sclerosis.
    Badawi AH; Siahaan TJ
    Clin Immunol; 2012 Aug; 144(2):127-38. PubMed ID: 22722227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hopeful prospects in multiple sclerosis.
    Bornstein MB
    Hosp Pract (Off Ed); 1992 May; 27(5):135-8, 141-2, 145-8 passim. PubMed ID: 1577883
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of experimental recombinant interferons on multiple sclerosis.
    Johnson KP; Panitch HS
    Trans Am Clin Climatol Assoc; 1989; 100():171-6. PubMed ID: 2479162
    [No Abstract]   [Full Text] [Related]  

  • 32. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial.
    Hohol MJ; Khoury SJ; Cook SL; Orav EJ; Hafler DA; Weiner HL
    Ann N Y Acad Sci; 1996 Feb; 778():243-50. PubMed ID: 8610977
    [No Abstract]   [Full Text] [Related]  

  • 33. Is there a place for 'immuno' in the immunotherapy of multiple sclerosis?
    Forsthuber TG; Muraro P
    Immunotherapy; 2009 May; 1(3):329-31. PubMed ID: 20635950
    [No Abstract]   [Full Text] [Related]  

  • 34. Antigen specific immunotherapy of multiple sclerosis.
    Steinman L; Conlon P
    J Clin Immunol; 2001 Mar; 21(2):93-8. PubMed ID: 11332658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections.
    Arnon R
    Immunol Lett; 1996 Apr; 50(1-2):1-15. PubMed ID: 8793553
    [No Abstract]   [Full Text] [Related]  

  • 36. Scientists probe strategies to repair neuron damage in multiple sclerosis.
    Kuehn BM
    JAMA; 2011 Mar; 305(9):871-2, 874. PubMed ID: 21364130
    [No Abstract]   [Full Text] [Related]  

  • 37. Liposome-encapsulated peptides protect against experimental allergic encephalitis.
    Belogurov AA; Stepanov AV; Smirnov IV; Melamed D; Bacon A; Mamedov AE; Boitsov VM; Sashchenko LP; Ponomarenko NA; Sharanova SN; Boyko AN; Dubina MV; Friboulet A; Genkin DD; Gabibov AG
    FASEB J; 2013 Jan; 27(1):222-31. PubMed ID: 23047895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management of multiple sclerosis.
    Compston DA
    Q J Med; 1989 Feb; 70(262):93-101. PubMed ID: 2687929
    [No Abstract]   [Full Text] [Related]  

  • 39. [Immunotherapy of multiple sclerosis].
    Sabouraud O; Edan G
    Rev Prat; 1989 Apr; 39(10):858-62. PubMed ID: 2740754
    [No Abstract]   [Full Text] [Related]  

  • 40. [The clinical picture of MS disease is now more complete].
    Panelius M; Salmi AA
    Duodecim; 1992; 108(1):73-5. PubMed ID: 1365986
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.